Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls

Table 2 Gastric acid and chloride secretion in patients with type 2 diabetes and healthy controls (mean±SE)

Experimental period:	Basal	Pentagastrin	Hyperglycemia	Placebo	GIP low	GIP high	Significance
Time (min):	(-90)	(-45 to -30)	(-15 to 0)	(45 to 60)	(105 to 120)	(165 to 180)	(P -value)
Healthy controls
H+ -secretion [mmol/15 min]	1.9 ± 0.4	6.2 ± 0.9	7.2 ± 0.7	8.1 ± 1.1	7.9 ± 1.0	6.5 ± 0.5	< 0.001
Cl- -secretion [mmol/15 min]	1.9 ± 0.4	7.9 ± 1.0	9.0 ± 0.8	9.9 ± 1.3	9.6 ± 1.2	8.0 ± 0.7	< 0.001
Patients with type 2 diabetes
H+ -secretion [mmol/15 min]	1.6 ± 0.4	8.3 ± 1.7	8.3 ± 1.7	9.5 ± 1.8	8.6 ± 1.7	8.2 ± 1.6	< 0.01
Cl- -secretion [mmol/15 min]	1.6 ± 0.4	11.1 ± 1.4	11.7 ± 2.1	12.5 ± 2.1	11.8 ± 1.7	11.4 ± 1.5	<0.001

Statistics: ANOVA